Despite respectable revenue growth, the company's share price has significantly underperformed the market over the past five years. Last year's performance suggests unresolved challenges, worse than the annualised loss of 8% over the last half decade.

Despite Landfar Bio-medicine's falling price and revenues, its high P/S ratio suggests investor optimism. However, inconsistent revenue growth and expected industry growth of 825% may make these prices unsustainable. Without significant medium-term performance improvement, the P/S ratio may decline to a more reasonable level.